Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
European Radiology
|
March 24, 2026
Negligible impact of perifissural nodules in an AI-first reader workflow from UK lung screening trial
Beibei Jiang, Daiwei Han, Jiali Cai, et al.
Plant Physiology and Biochemistry : PPB
|
September 18, 2025
Dual regulation of thermotolerance and drought tolerance by LrWRKY16 through LrHSP17.2-mediated homeostasis and ROS scavenging in Lilium regale
Peng Mei, Shaokang Tang, Qin Ling, et al.
Neoplasia (New York, N.Y.)
|
September 11, 2024
A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon
Xiao Yang, Huichen Bai, Xi Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2018
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky, Lijie Zhai, Alicia Lenzen, et al.
Plos Genetics
|
June 4, 2021
Novel EDGE encoding method enhances ability to identify genetic interactions
Molly A Hall, John Wallace, Anastasia M Lucas, et al.
Frontiers in Immunology
|
March 11, 2022
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
Xin Chen, Liu Xue, Xiao Ding, et al.
Neoplasia (New York, N.Y.)
|
July 12, 2020
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong, Yin Guo, Ye Liu, et al.
Frontiers of Medicine
|
September 25, 2023
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
Beibei Jiang, Tong Zhang, Minjuan Deng, et al.
Journal of Medicinal Chemistry
|
December 2, 2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang, Bo Ren, Ye Liu, et al.
Cardiovascular Research
|
April 20, 2021
Cis-epistasis at the LPA locus and risk of cardiovascular diseases
Lingyao Zeng, Sylvain Moser, Nazanin Mirza-Schreiber, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
European Radiology
|
March 24, 2026
Negligible impact of perifissural nodules in an AI-first reader workflow from UK lung screening trial
Beibei Jiang, Daiwei Han, Jiali Cai, et al.
Plant Physiology and Biochemistry : PPB
|
September 18, 2025
Dual regulation of thermotolerance and drought tolerance by LrWRKY16 through LrHSP17.2-mediated homeostasis and ROS scavenging in Lilium regale
Peng Mei, Shaokang Tang, Qin Ling, et al.
Neoplasia (New York, N.Y.)
|
September 11, 2024
A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon
Xiao Yang, Huichen Bai, Xi Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2018
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky, Lijie Zhai, Alicia Lenzen, et al.
Plos Genetics
|
June 4, 2021
Novel EDGE encoding method enhances ability to identify genetic interactions
Molly A Hall, John Wallace, Anastasia M Lucas, et al.
Frontiers in Immunology
|
March 11, 2022
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
Xin Chen, Liu Xue, Xiao Ding, et al.
Neoplasia (New York, N.Y.)
|
July 12, 2020
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong, Yin Guo, Ye Liu, et al.
Frontiers of Medicine
|
September 25, 2023
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models
Beibei Jiang, Tong Zhang, Minjuan Deng, et al.
Journal of Medicinal Chemistry
|
December 2, 2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang, Bo Ren, Ye Liu, et al.
Cardiovascular Research
|
April 20, 2021
Cis-epistasis at the LPA locus and risk of cardiovascular diseases
Lingyao Zeng, Sylvain Moser, Nazanin Mirza-Schreiber, et al.
Page
of 11